These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 16418784

  • 1. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA.
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [Abstract] [Full Text] [Related]

  • 2. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 3. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 5. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 7. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M, Levancini M.
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [Abstract] [Full Text] [Related]

  • 8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 9. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 10. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

  • 11. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [Abstract] [Full Text] [Related]

  • 12. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 13. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH, Baylink DJ, Crusan CE, Chines AA.
    J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
    [Abstract] [Full Text] [Related]

  • 14. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 May; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 15. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, EUROFORS Investigators.
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 17. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S.
    Osteoporos Int; 2000 May; 11(3):211-8. PubMed ID: 10824236
    [Abstract] [Full Text] [Related]

  • 18. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

  • 19. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 20. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P, Riis BJ, Christiansen C.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.